Wall Street Zen Upgrades Profound Medical (NASDAQ:PROF) to “Hold”

Profound Medical (NASDAQ:PROF) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

PROF has been the subject of several other research reports. Raymond James Financial raised Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price objective for the company in a research report on Monday, July 27th. Weiss Ratings raised Profound Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Profound Medical has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Profound Medical Price Performance

Profound Medical stock opened at $6.90 on Friday. The firm has a market cap of $252.26 million, a price-to-earnings ratio of -7.04 and a beta of 0.75. Profound Medical has a fifty-two week low of $4.80 and a fifty-two week high of $8.95. The firm has a fifty day moving average price of $6.57 and a two-hundred day moving average price of $6.70.

Profound Medical (NASDAQ:PROF) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The firm had revenue of $2.48 million for the quarter, compared to the consensus estimate of $4.75 million. Profound Medical had a negative net margin of 171.57% and a negative return on equity of 63.03%. As a group, sell-side analysts expect that Profound Medical will post -0.79 earnings per share for the current year.

Institutional Trading of Profound Medical

A number of hedge funds have recently bought and sold shares of the stock. Gagnon Securities LLC grew its position in Profound Medical by 12.2% in the 4th quarter. Gagnon Securities LLC now owns 1,944,061 shares of the company’s stock worth $15,300,000 after purchasing an additional 211,021 shares during the last quarter. Gagnon Advisors LLC increased its holdings in shares of Profound Medical by 7.3% during the 4th quarter. Gagnon Advisors LLC now owns 962,186 shares of the company’s stock worth $7,572,000 after purchasing an additional 65,515 shares during the period. Royal Bank of Canada raised its position in shares of Profound Medical by 4.2% during the first quarter. Royal Bank of Canada now owns 493,060 shares of the company’s stock valued at $3,195,000 after buying an additional 19,842 shares during the last quarter. Ardsley Advisory Partners LP raised its position in shares of Profound Medical by 36.4% during the fourth quarter. Ardsley Advisory Partners LP now owns 450,000 shares of the company’s stock valued at $3,542,000 after buying an additional 120,000 shares during the last quarter. Finally, Connective Capital Management LLC acquired a new position in shares of Profound Medical during the fourth quarter valued at about $787,000. 47.86% of the stock is owned by institutional investors.

Key Stories Impacting Profound Medical

Here are the key news stories impacting Profound Medical this week:

• Positive Sentiment: Raised Q3 revenue outlook: Profound Medical increased its third-quarter 2026 revenue outlook to a level above Wall Street expectations. The update helped drive a 21.7% share-price surge in the prior session and suggests stronger near-term commercial momentum for the TULSA-PRO platform. Profound Medical raises Q3 2026 revenue outlook above estimates
• Positive Sentiment: Telix co-education agreement: Profound and Telix Pharmaceuticals (ASX: TLX; NASDAQ: TLX) will educate urologists, radiologists, nuclear-medicine specialists and prostate-cancer centers on combining Telix’s PSMA-PET imaging products, Gozellix and Illuccix, with Profound’s MRI-guided, AI-powered TULSA-PRO treatment. The agreement could expand Profound’s access to urologists, support evidence-based patient selection and strengthen adoption of its prostate-treatment system. No financial terms were disclosed. Profound Medical and Telix Pharmaceuticals enter co-education agreement
• Neutral Sentiment: Analyst momentum remains uncertain: Coverage highlighted the improved revenue outlook and a rating upgrade, but noted that recent earnings-estimate revisions may not translate into additional near-term gains after the stock’s substantial rally. Profound Medical Q3 revenue beats outlook
• Neutral Sentiment: Short-interest data offers little signal: Reported short interest was zero shares as of October 9, with a zero-day days-to-cover ratio. While described as an increase, the figure does not indicate meaningful short-covering pressure or a likely short squeeze.

Profound Medical Company Profile

Profound Medical Corp. (NASDAQ:PROF) is a medical technology company focused on developing and commercializing incisionless therapies for localized prostate disease. The company’s flagship product is the TULSA-PRO system, which uses real-time magnetic resonance imaging (MRI) guidance and transurethral ultrasound to deliver controlled thermal ablation to targeted prostate tissue.

TULSA-PRO is designed to enable physicians to customize treatment based on a patient’s prostate anatomy and disease location.